Acuitas Therapeutics to showcase LNP delivery platform at four prestigious conferences in November 2025
Read about Acuitas Therapeutics to showcase LNP delivery platform at four prestigious conferences in November 2025
Business in Vancouver shines a spotlight on Acuitas Therapeutics in its Life Sciences 2025 feature
Read about Business in Vancouver shines a spotlight on Acuitas Therapeutics in its Life Sciences 2025 feature
Acuitas Therapeutics and collaborators demonstrate strong protection against P. vivax malaria with mRNA-LNP vaccine
Read about Acuitas Therapeutics and collaborators demonstrate strong protection against P. vivax malaria with mRNA-LNP vaccine
Acuitas Therapeutics announces oral presentations at the 2025 Alliance for mRNA Medicines’ Annual Meeting
Read about Acuitas Therapeutics announces oral presentations at the 2025 Alliance for mRNA Medicines’ Annual Meeting
Acuitas Therapeutics contributes to new insights into broadly neutralizing antibodies induced by COVID-19 mRNA vaccines
Read about Acuitas Therapeutics contributes to new insights into broadly neutralizing antibodies induced by COVID-19 mRNA vaccines
Acuitas Therapeutics’ scientists collaborate with the University of Zurich and the University of Pennsylvania to develop a novel deep learning model for efficient adenine base editing
Read about Acuitas Therapeutics’ scientists collaborate with the University of Zurich and the University of Pennsylvania to develop a novel deep learning model for efficient adenine base editing
Acuitas Therapeutics presents new method for mRNA-LNP production using preformed vesicles at CRS 2025
Read about Acuitas Therapeutics presents new method for mRNA-LNP production using preformed vesicles at CRS 2025
Acuitas Therapeutics and researchers at the University of Pennsylvania demonstrate enhanced T cell immunity with IL-12 mRNA-LNP adjuvant
Read about Acuitas Therapeutics and researchers at the University of Pennsylvania demonstrate enhanced T cell immunity with IL-12 mRNA-LNP adjuvant
Acuitas Therapeutics collaborates on mRNA-LNP prime editing study for genetic liver disease
Read about Acuitas Therapeutics collaborates on mRNA-LNP prime editing study for genetic liver disease
Malewana et al. (2025) “Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates” Science Translational Medicine.
DOI: 10.1126/scitranslmed.adn5651
Read about Malewana et al. (2025) “Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates” Science Translational Medicine.
Aunins et al. (2025) “An Il12 mRNA-LNP adjuvant enhances mRNA vaccine–induced CD8 T cell responses” Science Immunology.
DOI: 10.1126/sciimmunol.ads1328
Read about Aunins et al. (2025) “An Il12 mRNA-LNP adjuvant enhances mRNA vaccine–induced CD8 T cell responses” Science Immunology.
Rothgangl et al. (2025) “Treatment of a metabolic liver disease in mice with a transient prime editing approach” Nature Biomedical Engineering.
DOI: 10.1038/s41551-025-01399-4
Read about Rothgangl et al. (2025) “Treatment of a metabolic liver disease in mice with a transient prime editing approach” Nature Biomedical Engineering.